Organization
Guangzhou Patronus Biotech
9 clinical trials
Clinical trial
A Phase I, Randomized, Observer-blinded, Positive-Controlled, Dose Escalation Clinical Trial to Assess the Safety and Immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 YearsStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Randomized, Blinded, Placebo-Controlled, Dose Escalation Phase 1 Trial of Recombinant COVID-19 Trivalent (XBB.1+BQ.1.1+Prototype) Protein Vaccine (CHO Cell)(LYB002V14) in Booster Vaccination in Participants Aged 18 Years Old and AboveStatus: Not yet recruiting, Estimated PCD: 2024-12-26
Clinical trial
A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and AboveStatus: Active (not recruiting), Estimated PCD: 2023-01-10
Clinical trial
A Clinical Trial to Assess the Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Adults 18-59 Years of Age Completed Two- or Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-10-10
Clinical trial
To Evaluate the Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Trivalent Vaccine (CHO Cell) LYB002 in Chinese Adults 18 Years and Above Completed Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-07-31
Clinical trial
A Randomized, Blinded, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above(Negative for Antibody Against COVID-19)Status: Withdrawn, Estimated PCD: 2023-06-27
Clinical trial
Evaluate the Immunogenicity and Safety of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Above Who Have Completed Two-dose or Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-01-18
Clinical trial
A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or OlderStatus: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and OlderStatus: Not yet recruiting, Estimated PCD: 2025-02-01